The 144th Annual Meeting of the Pharmaceutical Society of Japan (Yokohama)

Organizer: Takashi Yoshikado (Yokohama Univ. Pharm.), Toshiyuki Kudo (Fac. Pharm., Musashino Univ.), Masanobu Sato (Nippon Boehringer Ingelheim), Yoshiyuki Shirasaka (Fac. Pharm., Kanazawa Univ.)

ADME, which determines human in vivo pharmacokinetics, can be subject to individual differences due to genetic and environmental factors. Moreover, when considering drug efficacy and side effects, variability can also arise due to factors such as the number of target molecules and their affinities. Considering the essence of drug development, it is considered essential to predict efficacy and side effects, taking individual differences into account, based not only on the understanding of ADME but also on information derived from biomarkers. This session, jointly organized with the Drug Interaction and Personalized Medicine Focus Group of the Academy of Pharmaceutical Science and Technology, Japan, aims to address how to approach individual differences caused by drug-metabolizing enzymes, transporters, plasma proteins, and even gut microbiota, based on the latest knowledge. Furthermore, discussions will focus on considering individual variabilities in clinical development, with a specific case regarding the dosage and administration setting of anti-PD-1 antibodies. We aim to deepen discussions with attendees on the common theme of "How pharmaceutical science and technology contribute to personalized medicine."